



# Becton, Dickinson & Co. (BDX)

Updated August 4<sup>th</sup>, 2024 by Nathan Parsh

## Key Metrics

<b>Current Price:</b>	\$242	<b>5 Year CAGR Estimate:</b>	9.9%	<b>Market Cap:</b>	\$70 B
<b>Fair Value Price:</b>	\$249	<b>5 Year Growth Estimate:</b>	8.0%	<b>Ex-Dividend Date:</b>	09/09/24
<b>% Fair Value:</b>	97%	<b>5 Year Valuation Multiple Estimate:</b>	0.6%	<b>Dividend Payment Date:</b>	09/30/24
<b>Dividend Yield:</b>	1.6%	<b>5 Year Price Target:</b>	\$366	<b>Years Of Dividend Growth:</b>	52
<b>Dividend Risk Score:</b>	A	<b>Retirement Suitability Score:</b>	B	<b>Rating:</b>	Buy

## Overview & Current Events

Becton, Dickinson & Co., or BD, is a global leader in the medical supply industry. The company was founded in 1897 and has 75,000 employees across 190 countries. The company generates about \$20 billion in annual revenue, with approximately 43% of revenues coming from outside of the U.S. BD is composed of three segments. Products sold by the Medical Division include needles for drug delivery systems, and surgical blades. The Life Sciences division provides products for the collection and transportation of diagnostic specimens. The Intervention segment includes several of the products produced by what used to be Bard.

On November 9<sup>th</sup>, 2023, BD increased its quarterly dividend 4.4% to \$0.95, extending the company's dividend growth streak to 52 consecutive years.

On August 1<sup>st</sup>, 2024, BD announced earnings results for the third quarter of fiscal year 2024, which ended June 30<sup>th</sup>, 2024. For the quarter, revenue grew 2.3% to \$5.1 billion, which \$87 million below estimates. On a currency neutral basis, revenue increased 2.9%. Adjusted earnings-per-share of \$3.50 compared favorably to \$2.96 in the prior year and was \$0.19 above expectations.

For the quarter, U.S. grew 4.3% while international was up 1.1% (down 0.3% on a reported basis). Organic growth was 5.2% for the period. The Medical segment grew 5.6% to \$2.56 billion as all businesses were up year-over-year once again. Mediation Management Solutions remains the top performer, thanks to strong demand for infusion systems. Life Science revenue was up 3.5% to \$1.26 billion as gains in Integrated Diagnostic Solutions was only partially offset by a slight decline in Biosciences. Interventional increased 6.4% to \$1.24 billion, driven once again by Urology and Critical Care. Surgery was down, but mostly due to a divestiture as all three businesses were up year-over-year.

BD provided an updated outlook for fiscal year 2024 as well. Revenue projections were narrowed to \$20.1 billion to \$20.3 billion, with the midpoint slightly below the market's expectation of \$20.25 billion. BD now expects organic growth in a range of 5.0% to 5.25% for the year, compared to 5.5% to 6.25% and 5.25% to 6.25% previously. Adjusted earnings-per-share is now projected to be in a range of \$13.05 to \$13.15, up from \$12.95 to \$13.15, \$12.82 to \$13.06, and \$12.70 to \$13.00 previously. We have updated our forecast accordingly.

## Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
<b>EPS</b>	\$6.25	\$7.16	\$8.59	\$9.48	\$11.01	\$11.68	\$10.19	\$13.08	\$11.35	\$12.21	<b>\$13.10</b>	<b>\$19.25</b>
<b>DPS</b>	\$2.18	\$2.40	\$2.64	\$2.92	\$3.02	\$3.08	\$3.16	\$3.32	\$3.48	\$3.64	<b>\$3.80</b>	<b>\$4.85</b>
<b>Shares<sup>1</sup></b>	192	211	213	228	265	265	293	289	287	293	<b>290</b>	<b>280</b>

BD has increased earnings-per-share 7.7% per year over the past decade, and has grown earnings in 9 out of the last 10 years. We feel that BD can grow earnings at a rate of 8% per year through fiscal 2029, down from 10% previously.

BD has now increased its dividend for 52 consecutive years. This makes the company a member of the Dividend Kings. The dividend has a compound annual growth rate of 5.9% over the last 10 years and 3.4% over the past five years. We

<sup>1</sup> In millions of shares

Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Becton, Dickinson & Co. (BDX)

Updated August 4<sup>th</sup>, 2024 by Nathan Parsh

expect that the dividend will grow by 5% annually over the next five years. The dividend growth streak is very likely to continue as BD has a low payout ratio leaving for plenty of room for additional increases.

## Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	18.1	19.5	18.4	19.4	20.8	20.8	24.7	18.8	19.6	21.2	18.5	19.0
Avg. Yld.	1.9%	1.7%	1.7%	1.7%	1.3%	1.3%	1.3%	1.4%	1.6%	1.4%	1.6%	1.3%

BD's stock has gained \$4, or 1.7%, since our May 7<sup>th</sup>, 2024 report. Based off estimates for fiscal year 2024, BD's stock currently has a price-to-earnings ratio of 18.5. Our target price-to-earnings ratio for fiscal year 2029 of 19 is near the long-term average. Valuation could add 0.6% to annual returns over the next five years. BD's current yield of 1.6% is slightly ahead of the stock's 10-year average yield of 1.5%.

## Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	35%	34%	31%	31%	27%	26%	31%	25%	31%	30%	29%	25%

BD showed that it can perform well in less than ideal economic conditions during the last recession. The company's key competitive advantage is that its products are in high demand as medical devices and other healthcare products are still sought out during a recession. People will seek medical care regardless of how the economy is performing. This ability to grow or maintain earnings in any economic climate makes BD a quality company and a safe stock. The acquisition of Bard has added to both the top and bottom lines and increases the company's exposure to China.

## Final Thoughts & Recommendation

Becton, Dickinson & Co. is expected to offer a total return of 9.9% annually over the next five years, down slightly from 10.2% previously. This is due to an 8% expected earnings growth rate, the 1.6% starting dividend yield, and a small contribution from multiple expansion. As with the prior quarter, results were strong in nearly every aspect of the company's business. Management raised its EPS guidance again for the year, though the revenue and organic growth forecasts were lowered. We have raised our five-year price target \$2 to \$366 due to EPS estimates for the fiscal year. We continue to rate shares of BD as a buy due to projected returns.

## Total Return Breakdown by Year



Disclosure: This analyst has no position in the security discussed in this research report, and no plans to initiate one in the next 72 hours.



# Becton, Dickinson & Co. (BDX)

Updated August 4<sup>th</sup>, 2024 by Nathan Parsh

## Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
<b>Revenue</b>	8446	10282	12483	12093	15983	17290	16074	19131	18870	19372
<b>Gross Profit</b>	4301	4695	5991	5965	7269	8288	6798	8631	8477	8170
<b>Gross Margin</b>	50.9%	45.7%	48.0%	49.3%	45.5%	47.9%	42.3%	45.1%	44.9%	42.2%
<b>SG&amp;A Exp.</b>	2145	2563	3005	2909	4016	4332	4185	4719	4709	4719
<b>D&amp;A Exp.</b>	562	891	1114	1088	1978	2253	2115	2230	2229	2288
<b>Operating Profit</b>	1606	1500	2158	1876	2249	2240	1211	2430	2475	2424
<b>Operating Margin</b>	19.0%	14.6%	17.3%	15.5%	14.1%	13.0%	7.5%	12.7%	13.1%	12.5%
<b>Net Profit</b>	1185	695	976	1100	311	1233	874	2092	1779	1484
<b>Net Margin</b>	14.0%	6.8%	7.8%	9.1%	1.9%	7.1%	5.4%	10.9%	9.4%	7.7%
<b>Free Cash Flow</b>	1091	1133	1866	1823	1970	2373	2770	3454	1661	2115
<b>Income Tax</b>	337	44	97	(124)	862	(57)	62	88	148	132

## Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
<b>Total Assets</b>	12447	26478	25586	37734	53904	51765	54012	53880	52934	52780
<b>Cash &amp; Equivalents</b>	1861	1424	1541	14179	1140	536	2825	2283	1006	1416
<b>Accounts Receivable</b>	1187	1618	1618	1744	2319	2345	2398	2350	2191	2534
<b>Inventories</b>	1495	1959	1719	1818	2451	2579	2743	2743	3224	3273
<b>Goodwill &amp; Int. Ass.</b>	2217	14924	13700	13456	40041	38353	37433	36670	36932	35469
<b>Total Liabilities</b>	7394	19313	17952	24786	32910	30683	30247	30203	27652	26984
<b>Accounts Payable</b>	401	631	665	797	1106	1092	1355	1739	1699	1641
<b>Long-Term Debt</b>	3971	12822	11551	18870	21495	19390	17930	17610	16065	15879
<b>Shareholder's Equity</b>	5053	7165	7634	12946	20992	21080	23763	23675	25280	25796
<b>LTD/E Ratio</b>	0.79	1.79	1.51	1.46	1.02	0.92	0.75	0.74	0.64	0.62

## Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
<b>Return on Assets</b>	9.6%	3.6%	3.7%	3.5%	0.7%	2.3%	1.7%	3.9%	3.3%	2.8%
<b>Return on Equity</b>	23.5%	11.4%	13.2%	10.7%	1.8%	5.9%	3.9%	8.8%	7.3%	5.8%
<b>ROIC</b>	13.1%	4.8%	5.0%	4.3%	0.8%	3.0%	2.1%	5.0%	4.3%	3.6%
<b>Shares Out.</b>	192	211	213	228	265	265	293	289	287	293
<b>Revenue/Share</b>	42.72	49.55	57.38	54.09	60.40	62.92	56.92	65.50	65.67	67.17
<b>FCF/Share</b>	5.52	5.46	8.58	8.15	7.44	8.64	9.81	11.83	5.78	7.33

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.